Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Outcomes among secondary prevention implantable cardioverter-defibrillator recipients aged ≥80 years at time of implant in the West of Scotland: A 7-year retrospective review.

Scottish medical journal·2026

Same author

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.

Lancet (London, England)·2026

Same author

Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System.

Journal of the American College of Cardiology·2026

Same author

Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.

European journal of heart failure·2026

Same author

SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure.

European journal of heart failure·2026

Same author

Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.

European heart journal·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

B-type natriuretic peptides in heart failure.

Roy S Gardner¹, Kwok S Chong, Theresa A McDonagh

¹Royal Infirmary, Scottish National Advanced Heart Failure Service, Department of Cardiology, Glasgow, UK. rsgardner@doctors.org.uk

Biomarkers in Medicine

|May 19, 2010

Summary

B-type natriuretic peptides are valuable for diagnosing heart failure and predicting adverse outcomes. Research is exploring their therapeutic potential in decompensated heart failure and advanced cases.

More Related Videos

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Jun 13, 2026

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Area of Science:

Biochemistry
Cardiology
Clinical Medicine

Background:

B-type natriuretic peptides (BNP) are increasingly recognized for their clinical utility.
Research has primarily focused on heart failure diagnosis and prognosis.
Their role extends beyond diagnosis to predicting adverse outcomes.

Purpose of the Study:

To review current and established data on B-type natriuretic peptides.
To emphasize their significance in advanced heart failure management.
To explore their potential as a therapeutic agent.

Main Methods:

Literature review of contemporary and established research.
Focus on studies related to heart failure, particularly advanced stages.
Analysis of diagnostic and prognostic applications.

Main Results:

BNP has strong negative predictive value for heart failure diagnosis.
BNP levels powerfully predict adverse outcomes, aiding risk stratification.
BNP is being investigated for therapeutic use in decompensated heart failure.

Conclusions:

B-type natriuretic peptides are crucial biomarkers in cardiology.
Their predictive power is vital for managing advanced heart failure and resource allocation.
Ongoing research may expand their therapeutic applications.